Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Peptide nucleic acids are synthetic polymers that mimic the structure of DNA or RNA. PNAs are used in various molecular biology techniques involving specific recognition of a complementary DNA or RNA strand and have been investigated as the basis for diagnostics and antisense therapies.
Accurate single nucleotide variations (SNVs) detection is clinically vital, yet existing techniques can only detect SNVs at specific loci. Here, Mao et al present a new generalized CRISPR/Cas-based strategy, termed PRICE, to identify SNVs in miRNA sequences without sacrificing the sensitivity.
Transcription factors are crucial in disease but hard to target with traditional drugs. Here, authors present BlockerSELEX, a strategy to develop inhibitory aptamers that block transcription factor interactions, which disrupts interactions between key proteins, showing potential for new nucleic acid therapies.
Off-target toxicity of antisense oligonucleotides (ASOs) poses a challenge for their clinical use. Here, authors develop a toehold-bearing ASO architecture that mitigates a broad spectrum of off-target interactions, significantly enhancing the safety profile of ASO drugs.
Findeisen et al. have engineered IC7Fc, a cytokine for the treatment of type 2 diabetes, that selectively activates beneficial metabolic pathways systemically and in metabolic tissues without promoting an inflammatory response.
A process in which peptide nucleic acids may be used for in vitro evolution has been developed. This method can offer enormous opportunities to evolve stable, non-natural molecules for therapeutic applications.
